Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel

Basit Öğe Kaydı
dc.authorid0000-0002-4368-0777
dc.contributor.authorYılmaz, Akın
dc.contributor.authorAlp, Ebru
dc.contributor.authorÖnen, İlke Hacer
dc.contributor.authorMenevşe, Emine Sevda
dc.date.accessioned2019-05-13T09:03:51Z
dc.date.available2019-05-13T09:03:51Z
dc.date.issued2016
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractAim of the study: Cervical cancer is the second most common malignancy in women worldwide. Everolimus displays direct effects on growth and proliferation of cancer cells via inhibition of mammalian target of rapamycin (mTOR) protein, which is known to be associated with drug resistance. In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes. Material and methods: HeLa cells were treated with different doses of everolimus, gemcitabine, and paclitaxel. Cell viability was assessed using MTT assay, and obtained dose response curves were used for the calculations of inhibitory concentration (IC) values. At the end of the treatment times with selected doses, RNA isolation and cDNA synthesis were performed. Finally, GRP78, CCND1, CASP2, and BCL2 genes mRNA expression levels were analysed using quantitative PCR. Results: The IC50 value of everolimus was 0.9 M for 24-hour treatment. Moreover, the IC50 value of gemcitabine and paclitaxel was found to be around 18.1 M and 7.08 M, respectively. Everolimus, gemcitabine, and paclitaxel treatments alone did not change the GRP78, CCND1, BCL2 and CASP2 mRNA expression levels significantly. However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p < 0.05). In contrast, this combination did not change GRP78 and CASP2 mRNA expression levels (p > 0.05). Conclusions: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers.
dc.identifier.citationYılmaz, A., Alp, E., Önen, H. İ., Menevşe, S. (2016). Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Contemporary Oncology, 20(1), 28-32.
dc.identifier.doi10.5114/wo.2016.58498
dc.identifier.endpage32en_US
dc.identifier.issn1428-2526
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage28en_US
dc.identifier.urihttps://doi.org/10.5114/wo.2016.58498
dc.identifier.urihttps://hdl.handle.net/11491/1547
dc.identifier.volume20en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd.
dc.relation.ispartofContemporary Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBCL2en_US
dc.subjectCASP2en_US
dc.subjectCCND1en_US
dc.subjectEverolimusen_US
dc.subjectGene Expressionen_US
dc.subjectGRP78en_US
dc.subjectHeLa Cellsen_US
dc.subjectPaclitaxelen_US
dc.subjectUnfolded Protein Responseen_US
dc.titleReduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
yilmazakin.pdf
Boyut:
73.2 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu